Bispecific antibodies and fusion proteins that bind to EBOV and NPC1
US10377815B2 · kind B2 · utility
1Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2016 |
| Grant date | Aug 13, 2019 |
| Priority date | — |
| Expiry date | May 4, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/14111
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.